These analyses have identified conjunctival staining and ocular pain as the highest potential "sign" and "symptom" co-primary endpoints to be explored in the next DED trial of OK-101
Save time and jump to the most important pieces.
6-K - OKYO Pharma Ltd (0001849296) (Filer)
6-K - OKYO Pharma Ltd (0001849296) (Filer)
6-K - OKYO Pharma Ltd (0001849296) (Filer)
4 - OKYO Pharma Ltd (0001849296) (Issuer)
4 - OKYO Pharma Ltd (0001849296) (Issuer)
ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (NASDAQ:OKYO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:MUSQ: https://www.redchip.com/assets/access/musq_accessOKYO: https://www.redchip.com/assets/access/okyo_accessIn an exclusive interview, David Schulhof, Founder and CEO of MUSQ LLC, the company behind the MUSQ Global Music Industry ETF, appears on the RedChip Small Stocks Bi
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it will be presenting at the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy during October 30 - November 2, 2024. The OKYO management team will be participating in one-on-one meetings to discuss the dry eye disease trial results, and also the recent opening of our Phase 2 trial of O
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 is the first IND granted by FDA to treat patients with NCP LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain (NCP), an ocular condition associated with pain but without an FDA-approved therapy, is pleased to announce that the first patient has been dosed in the Phase 2 trial of topi
4 - OKYO Pharma Ltd (0001849296) (Issuer)
HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer. Mr Clementi will formally take up the COO role effective September 1, 2023. Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team. Dr. Clementi has followed a science-driven career path since completing his NIH Training Fellows
LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ((LSE: OKYO, NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and Medical Director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to OKYO's Scientific Advisory Board (SAB). In this role Dr. Pepose will help guide OKYO's clinical programs for OK-101 for the treatment of DED. The Company anticipates opening its Phase 2 clinical trial of OK-10
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ((LSE: OKYO, NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announces that the board of directors of the Company (the "Board" or "Directors"), has appointed PKF Littlejohn LLP ("PKF") as its new independent auditor with immediate effect. The Board has approved the appointment of PKF as the Company's auditor for the financial year ending 31 March 2023. The re-appointment of PKF for the financial year ending 31 March 2024 will be subject to approval by shareh
ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (NASDAQ:OKYO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:MUSQ: https://www.redchip.com/assets/access/musq_accessOKYO: https://www.redchip.com/assets/access/okyo_accessIn an exclusive interview, David Schulhof, Founder and CEO of MUSQ LLC, the company behind the MUSQ Global Music Industry ETF, appears on the RedChip Small Stocks Bi
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 50,000 of the Company's ordinary shares on NASDAQ at a price of US$1.03 per share. This brings the total shar
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 80,000 of the Company's ordinary shares on NASDAQ at a price of US$1.15 per share. This brings the total share